Vertex Pharmaceuticals: Three Things the Street Is Saying, and What the Filings Actually Show
Vertex spent most of the last decade as a one-disease company that happened to be extraordinarily...
Alphabet’s Margins Are the Best They’ve Ever Been. The Stock Assumes They Stay That Way Forever.
A 34% operating margin and a share price sitting meaningfully below its peak: those two facts...
Merck’s Split Screen: Margins at a Decade High, a Stock Priced for Catastrophe
Two numbers sit side by side and refuse to make sense together. The 10-K filed in...
Mirum Pharmaceuticals: A Pipeline on Fire, a Price That Went Cold
Three Phase 3 trials hit their primary endpoints in the span of two weeks. The stock...
Costco at $948: The Filed Numbers vs. What the Price Tag Demands
A stock sitting well below its 52-week high while posting the best operating margin in at...
Opko Health: A $1.46 Stock Priced Like a Winner, Filing Like a Turnaround in Progress
Before anything else The filed numbers show a company whose revenue has fallen roughly two-thirds from...
Ultragenyx: A Stock at Its Cheapest in a Decade, and the One Number That Explains Why
The stock trades at $15.22. The company is guiding toward its first profitable year. Two FDA...
Regeneron Is Earning More Than Ever. The Stock Acts Like It Barely Noticed.
For most of its life, Regeneron was a science project that happened to have a stock...
Emergent BioSolutions: The Quarter That Beat the Forecast, and the Write-Down That Buried the Headline
Emergent BioSolutions once made headlines as the company the U.S. government called when it needed vaccines...
Zoetis: The Market’s Collapse Thesis vs. What the Filings Show
For most of its first decade as a public company, Zoetis was the kind of business...
BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.